Ovarian Cancer Coverage from Every Angle

Ursula A. Matulonis, MD, on Educating Patients About the Hematologic Risks of PARP Inhibitors

Posted: Monday, August 5, 2019

How do you talk to patients about the potential risk for myelodysplastic syndromes and acute myeloid leukemia when taking rucaparib and other PARP inhibitors?

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.